✦ LIBER ✦

Melanocortin-4 Receptor (MC4R) Agonists for the Treatment of Obesity.

✍ Scribed by Ravi P. Nargund; Alison M. Strack; Tung M. Fong

Publisher: John Wiley and Sons
Year: 2006
Weight: 15 KB
Volume: 37
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200639259

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder in obese melanocortin-4-receptor (MC4R) deficient subjects: A newly described expression of MC4R deficiency

✍ Anat Agranat-Meged; Yoad Ghanadri; Iris Eisenberg; Ziva Ben Neriah; Eva Kieselst 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

Synthesis and Biological Evaluation of I

Synthesis and Biological Evaluation of Imidazole-Based Small Molecule Antagonists of the Melanocortin 4 Receptor (MC4-R).

✍ Thomas H. Marsilje; et al. et al. 📂 Article 📅 2004 🏛 John Wiley and Sons ⚖ 23 KB 👁 1 views

Design and Syntheses of Melanocortin Sub

Design and Syntheses of Melanocortin Subtype-4 Receptor Agonists: Evolution of the Pyridazinone Archetype.

✍ Feroze Ujjainwalla; et al. et al. 📂 Article 📅 2004 🏛 John Wiley and Sons ⚖ 141 KB

The Discovery of Taranabant, a Selective

The Discovery of Taranabant, a Selective Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

✍ William K. Hagmann 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 817 KB

ChemInform Abstract: The Discovery of Ta

ChemInform Abstract: The Discovery of Taranabant, a Selective Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

✍ William K. Hagmann 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 23 KB 👁 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

Discovery and SAR of New Benzazepines as

Discovery and SAR of New Benzazepines as Potent and Selective 5-HT2 Receptor Agonists for the Treatment of Obesity.

✍ Brian M. Smith; et al. et al. 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 21 KB 👁 1 views